Bacterial cellulose regenerative platform

Advancing Regenerative Therapies for Chronic Wounds

Komava Biotherapeutics is developing a next-generation regenerative wound care platform designed to move beyond conventional wound management, combining a bacterial cellulose scaffold, sustained antimicrobial activity and the controlled delivery of regenerative bioactive signals.

Explore the science Discover Komava

Structure Biomaterial scaffold (BC)

Hydration Wound environment

Protection Antimicrobial protection

Signalling Acellular regenerative payload

The unmet need

Chronic wounds don’t simply need to be covered. They need the biological conditions to heal.

Despite the availability of modern dressings and advanced care protocols, current treatments remain largely supportive, addressing moisture balance and infection control but failing to actively restore the biological processes required for effective tissue repair.

Modern dressings and advanced care protocols largely support wound management: moisture balance, protection, infection control. They address the environment around the wound rather than the biological mechanisms that have stalled inside it. Komava is developing a platform intended to address those additional barriers to tissue repair.

Why chronic wounds fail to heal

Mechanism of action

From a stalled wound to a regenerative environment.

A chronic wound is not simply an open wound that is taking a long time. It is a wound held in a biological state that prevents repair. The Komava platform is designed to act on that state directly.

The chronic wound microenvironment Four biological barriers keep a chronic wound from progressing through normal repair.

01 · The problem

The chronic wound microenvironment

Chronic wounds are hypoxic and inflammatory by nature, frequently subject to bacterial infection, and notoriously resistant to conventional therapy. The wound bed is held in a self-sustaining state in which the signals that would normally drive repair are degraded faster than they can act.

Biofilm and infectionBacterial colonisation and biofilm formation can create major barriers to healing in chronic wounds.

Chronic inflammationPersistent inflammation prevents normal progression toward proliferation and tissue repair.

Protease excessElevated protease activity can degrade the extracellular matrix and bioactive signals required for tissue repair.

Impaired regenerationAngiogenesis, extracellular matrix formation and re-epithelialisation are impaired, limiting effective tissue regeneration.

02 · The platform

The Komava advanced bioactive platform

The platform integrates three essential therapeutic functions within a single system: maintenance of a moist and protective wound environment, control of infection through antimicrobial activity, and controlled delivery of bioactive signals intended to reactivate tissue regeneration.

BC scaffoldBacterial cellulose provides structural integrity, high water retention and close adherence to the wound surface.

Hydrogel matrixMaintains a moist, protective wound environment and carries the acellular regenerative payload.

Bioactive signalsDesigned to deliver regenerative signals into the wound bed in a controlled way.

Antimicrobial protectionSustained activity designed to control bacterial colonisation and biofilm formation.

03 · The objective

A regenerative wound microenvironment

By restoring a permissive local environment, the platform is designed to enable effective tissue repair.

Biofilm controlledDesigned to control bacterial colonisation and biofilm formation in the wound bed.

Inflammation reducedIntended to reduce the biological barriers associated with chronic inflammation.

Angiogenesis supportedIntended to support the angiogenic processes required for tissue perfusion.

Matrix remodellingIntended to support extracellular matrix production and remodelling.

Re-epithelialisationIntended to support granulation and re-epithelialisation of the wound.

The Komava platform

One integrated regenerative approach

Komava combines complementary technologies within a single advanced wound dressing. The platform integrates three essential therapeutic functions within a single system: maintenance of a moist and protective wound environment, control of infection through antimicrobial activity, and controlled delivery of bioactive signals designed to restore key biological processes involved in tissue regeneration.

Biomaterial scaffold (BC)

Bacterial cellulose is a nanofibrous biomaterial produced by bacterial fermentation. Its dense, randomly oriented fibril network provides structural integrity, high water retention and close adherence to the wound surface.

Wound environment

A hydrogel environment maintained across the wound surface, designed to preserve tissue hydration and prevent desiccation.

Antimicrobial protection

Sustained antimicrobial activity, designed to control the bacterial colonisation and biofilm formation that act as major barriers to healing.

Acellular regenerative payload

Selected acellular regenerative payloads are incorporated within the platform for local and controlled delivery at the wound site. They are designed to restore key biological signals disrupted in chronic wounds and support essential repair processes, including cell migration and proliferation, angiogenesis and extracellular matrix formation.

How the platform works Indications and pipeline

Lead indication

Neuroischemic Diabetic Foot Ulcers.

Komava’s initial focus is on three chronic wound indications associated with significant morbidity, reduced quality of life and a substantial healthcare burden.

DFU

Diabetic Foot Ulcers

Lead indication

Diabetic foot ulcers are a serious complication of diabetes and remain a major cause of morbidity, hospitalisation and lower-limb amputation.

Komava has selected neuroischemic diabetic foot ulcers as its lead indication, where impaired perfusion, neuropathy and disrupted tissue repair create multiple biological barriers to healing.

18.6 million estimated new diabetic foot ulcers each year, worldwide Int J Environ Res Public Health. 2025 Mar 21;22(4):463.

VLU

Venous Leg Ulcers

Venous leg ulcers are chronic wounds associated with venous hypertension, persistent inflammation and microcirculatory dysfunction.

Their high prevalence, particularly in ageing populations, represents an important potential expansion opportunity for the Komava platform.

1 to 3% estimated lifetime prevalence in the general population in Western countries Journal of Tissue Viability, Volume 34, Issue 1, February 2025.

Pressure Ulcers

Pressure ulcers result from prolonged mechanical loading and tissue ischaemia and remain a significant challenge in hospital, long-term care and home-care settings.

The combination of ischaemia, inflammation and impaired tissue regeneration makes pressure ulcers another potential application for Komava’s regenerative platform.

2.47 million estimated new pressure ulcer cases globally in 2021 Front Public Health. 2025 Feb 26;13. Wound Repair Regen. 2025 Jul 11;33(4):e70064.

See the pipeline

Leadership

Built by people who have taken biotechnology from science to reality.

Komava is led by an executive team with deep experience in company management, product development, clinical trials, regulatory strategy, intellectual property, and go-to-market and post-market strategy.

Portrait of Ahmed Bouzidi, Co-Founder, Director and Chief Executive Officer of Komava Biotherapeutics.

Ahmed Bouzidi^{PhD, MBA}

Co-Founder, Director & Chief Executive Officer

30+ years in biotechnology

Ahmed’s senior executive experience in the biotechnology industry spans more than 30 years across Europe, China and the United States.

Portrait of Mylène Talabardon, Co-Founder, President and Chief Scientific Officer of Komava Biotherapeutics.

Mylène Talabardon^PhD

Co-Founder, President & Chief Scientific Officer

25+ years in biotechnology

Mylène brings 25 years of extensive experience in the biotechnology industry, with senior CMC leadership roles at Biogen, Sanofi and Merck Serono.

Hervé Broly^PhD

Chief Technology Officer

40+ years in bioprocess development

Hervé is an internationally recognised bioprocess expert with more than 40 years of experience in the development, manufacture and validation of biotechnology processes.

Full biographies

Partnering

A platform designed to be built with partners.

Komava is developing a modular bacterial cellulose platform for chronic wounds, combining an advanced biomaterial with locally delivered acellular regenerative payloads across three targeted indications.

Focus: Chronic wounds
Lead indication: Neuroischemic diabetic foot ulcers
Pipeline: Three targeted chronic wound indications
Headquarters: Paris, France

Partner with Komava Contact the team